Novartis’ Vas Narasimhan heads to Anthropic’s board; Metsera alum joins Structure as COOnews2026-04-17T11:00:50+00:00April 17th, 2026|Endpoints News|
RFK Jr. defends FDA, Makary following Republican questionsnews2026-04-16T19:03:14+00:00April 16th, 2026|Endpoints News|
OpenAI launches biopharma-focused AI model to compete with Anthropicnews2026-04-16T19:00:34+00:00April 16th, 2026|Endpoints News|
Cochrane review dismissing amyloid drugs draws immediate backlashnews2026-04-16T15:46:21+00:00April 16th, 2026|Endpoints News|
Roche to start a new Phase 3 trial for Elevidysnews2026-04-16T15:35:05+00:00April 16th, 2026|Endpoints News|
MeiraGTx buys back gene therapy from J&J; Storm brings in $56M Series Cnews2026-04-16T15:21:54+00:00April 16th, 2026|Endpoints News|
Using versus selling lucrative PRVs: Moderna’s cautionary talenews2026-04-16T14:21:31+00:00April 16th, 2026|Endpoints News|
MSF says Gilead’s lenacapavir supply ‘not nearly enough’; PolyPeptide’s strategic reviewnews2026-04-16T14:00:25+00:00April 16th, 2026|Endpoints News|
Lilly’s obesity pill heads for diabetes filing after heart risk trialnews2026-04-16T11:26:00+00:00April 16th, 2026|Endpoints News|
